Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC)

被引：0
|
作者：
Seidman, A. D.
Conlin, A. K.
Bach, A.
Brufsky, A. M.
Saleh, M. N.
Lake, D.
Dickler, M. N.
D'Andrea, G.
Traina, T. A.
Hudis, C. A.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[3] Georgia Canc Specialists, Marietta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.1047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1047
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer
    Infante, Jeffrey R.
    Yardley, Denise A.
    Burris, Howard A., III
    Greco, F. Anthony
    Farley, Cindy P.
    Webb, Charles
    Spigel, David R.
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (01) : 23 - 28
  • [32] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    Lin, N. U.
    Seah, D. S.
    Gelman, R.
    Desantis, S.
    Mayer, E. L.
    Isakoff, S.
    DiPiro, P.
    Krop, I. E.
    Come, S. E.
    Weckstein, D.
    Winer, E. P.
    Burstein, H. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 403 - 410
  • [33] Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
    Roy, V.
    LaPlant, B. R.
    Gross, G. G.
    Bane, C. L.
    Palmieri, F. M.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 449 - 453
  • [34] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    N. U. Lin
    D. S. Seah
    R. Gelman
    S. Desantis
    E. L. Mayer
    S. Isakoff
    P. DiPiro
    I. E. Krop
    S. E. Come
    D. Weckstein
    E. P. Winer
    H. J. Burstein
    Breast Cancer Research and Treatment, 2013, 139 : 403 - 410
  • [35] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Datko, F.
    D'Andrea, G.
    Dickler, M.
    Theodoulou, M.
    Goldfarb, S.
    Lake, D.
    Fornier, M.
    Modi, S.
    Sklarin, N.
    Comen, E.
    Fasano, J.
    Gajria, D.
    Drullinsky, P.
    Gilewski, T.
    Murphy, C.
    Syldor, A.
    Lau, A.
    Hamilton, N.
    Patil, S.
    Liu, J.
    Chandarlapaty, S.
    Hudis, C.
    Dang, C.
    CANCER RESEARCH, 2012, 72
  • [36] A report of cardiac events in a phase II clinical study using trastuzumab combined with pertuzumab in HER2-positive metastatic breast cancer (MBC)
    Portera, C. C.
    Walshe, J. M.
    Denduluri, N.
    Berman, A. W.
    Vatas, U.
    Rosing, D. R.
    Chow, C. K.
    Swain, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
    Gluck, S.
    Lobo, C.
    Reis, I.
    Lopes, G.
    Carmody, C.
    Tukia, K.
    Hurley, J.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [39] Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
    Conlin, A. K.
    Hudis, C. A.
    Bach, A.
    Moynahan, M.
    Lake, D.
    Forero-Torres, A.
    Wright, G.
    Hackney, M.
    Clawson, A.
    Seidman, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer
    Sonke, Gabe S.
    Mandjes, Ingrid A.
    Holtkamp, Marjo J.
    Schot, Margaret
    van Werkhoven, Erik
    Wesseling, Jelle
    Peeters, Marie-Jeanne Vrancken
    Rodenhuis, Sjoerd
    Linn, Sabine C.
    BREAST JOURNAL, 2013, 19 (04): : 419 - 426
12345